Clinical Trials Browser

Phase 1 × Interventional × Parkinson Disease 4, Autosomal Dominant Lewy Body × Clear all

NCT07161414 2026-03-17

ARTEMIDE-subQ

Phase 1 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT05853367 2026-03-13

MK-0472-001

Phase 1 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT05017012 2026-01-08

MK-3475A-C18

Phase 1 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT06460961 2025-12-31

MK-6837-001

Phase 1 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Neoplasm Metastasis

NCT06049212 2025-12-19

TroFuse-008

Phase 1 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT03010176 2025-10-29

MK-1454-001

Phase 1 Completed

156 enrolled 20 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lymphoma

NCT02964013 2025-10-14

KEYVIBE-001

Phase 1 Completed

474 enrolled 39 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Neoplasms

NCT04000529 2025-09-30

Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

Phase 1 Terminated

GastrointestinalHead & NeckSarcomaThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Gastrointestinal Stromal Tumors

NCT04458259 2025-08-28

Study of PF-07265807 in Participants With Metastatic Solid Tumors.

Phase 1 Terminated

DermatologicGastrointestinalGenitourinaryGynecologicThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Small Cell Lung Carcinoma

NCT02903914 2025-08-05

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

Phase 1 Completed

260 enrolled 52 charts

GastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms

NCT04153565 2025-07-17

MK-3475-A17

Phase 1 Completed

19 enrolled 14 charts

Other solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Mesothelioma

NCT05594043 2025-06-19

MK-6598-001

Phase 1 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT04317066 2025-04-06

KEYNOTE-A33

Phase 1 Completed

7 enrolled 13 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lymphoma, B-Cell

NCT03374254 2024-11-21

KEYNOTE-651

Phase 1 Completed

116 enrolled 18 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Spinocerebellar Degenerations, Colorectal Neoplasms

NCT05382325 2024-11-14

MK-1484-001

Phase 1 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT04135352 2024-11-12

V938-001

Phase 1 Terminated

35 enrolled 21 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Neoplasm Metastasis

NCT03833427 2024-11-07

MK-5618-001

Phase 1 Terminated

32 enrolled 17 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT03666273 2024-05-28

Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1.

Phase 1 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT02054806 2023-10-30

MK-3475-028

Phase 1 Completed

477 enrolled 14 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT02835690 2022-10-26

MK-3475-032

Phase 1 Completed

44 enrolled 24 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT03739138 2022-02-28

MK-4621-002

Phase 1 Terminated

30 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT02403193 2022-01-12

AdenONCO

Phase 1 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT02983006 2021-10-18

Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma

Phase 1 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT03515824 2021-03-09

MK-1697-001

Phase 1 Terminated

22 enrolled 18 charts

GastrointestinalHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Head and Neck Neoplasms, Neoplasms, Colorectal Neoplasms

NCT02622074 2020-09-10

KEYNOTE 173

Phase 1 Completed

60 enrolled 26 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT03545815 2020-08-10

Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.

Phase 1 Unknown

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT03920839 2020-04-24

INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)

Phase 1 Withdrawn

Other solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung

NCT01295827 2019-12-13

KEYNOTE-001

Phase 1 Completed

1,260 enrolled 45 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Melanoma, Neoplasm Metastasis, Neoplasms

NCT03099161 2019-06-05

MK-3814A-062

Phase 1 Terminated

10 enrolled 13 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Neoplasms

NCT02027961 2019-05-17

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Phase 1 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma, Neoplasm Metastasis